Table 1 Baseline characteristics of patients with CLL and RS.

From: Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome

 

CLL

RS

Number

33

37

Age, median (range)

69 (44–84)

67 (42–84)

Sex, female

13 (39%)

8 (22%)

Rai stagea

 0

3 (10%)

7 (21%)

 I–II

10 (32%)

12 (35%)

 III–IV

18 (58%)

15 (44%)

IgHV, unmutated

20/26 (77%)

31/35 (89%)

CLL FISH

 17p-

8 (29%)

9 (28%)

 11q-

4 (14%)

4 (13%)

 Trisomy 12

4 (14%)

2 (6%)

 Normal

5 (18%)

12 (38%)

 13q-

5 (18%)

4 (13%)

 Other abnormalities

2 (7%)

1 (3%)

TP53 disruption

9/28 (32%)

14/31 (45%)

CLL-IPIa

 0–1 (low risk)

1 (4%)

0 (0%)

 2–3 (intermediate risk)

2 (8%)

6 (19%)

 4–6 (high risk)

13 (54%)

11 (35%)

 7–10 (very high risk)

8 (33%)

14 (45%)

Prior treatment

 CIT only

20 (61%)

20 (54%)

 Ibrutinibb

13 (39%)

17 (46%)

  1. CLL chronic lymphocytic leukemia, RS Richter syndrome, IGHV immunoglobulin heavy chain variable region, FISH fluorescence in situ hybridization, IPI international prognostic index, CIT chemoimmunotherapy.
  2. aRai stage and CLL-IPI evaluation were based on evaluation of the CLL component at or near the time of sampling (closest data within 3 years).
  3. bAlso received CIT for CLL or RS.
Back to article page